Mostrando 10 resultados de: 16
Filtros aplicados
Subtipo de publicación
Article(16)
Publisher
Gastroenterology(2)
The Lancet(2)
The Lancet Diabetes and Endocrinology(2)
Canadian Journal of Cardiology(1)
Cardiovascular Diabetology(1)
Área temáticas
Enfermedades(15)
Farmacología y terapéutica(9)
Medicina y salud(7)
Fisiología humana(4)
Alimentación y bebidas(1)
Área de conocimiento
Medicina interna(10)
Diabetes(8)
Medicamento(5)
Enfermedad cardiovascular(3)
Cognición(2)
Origen
scopus(16)
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis
ArticleAbstract: BACKGROUND: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be thePalabras claves:aspirin, hemorrhage, neoplasms, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Berkowitz S.D., Bhatt D.L., Bosch J.J., Connolly S.J., Cook-Bruns N., Eikelboom J.W., Felix Camilo, Fox K.A.A., Hart R.G., Maggioni A.P., Moayyedi P., O’Donnell M., Rydén L.E., Shestakovska O., Verhamme P.B., Widimsky P., Yusuf S., Zhu J.Fuentes:googlescopusErectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
ArticleAbstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 rPalabras claves:Autores:Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.Fuentes:googlescopusEffect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
ArticleAbstract: Background: Diabetes is an independent risk factor for cognitive impairment. We aimed to investigatePalabras claves:Autores:Atisso C.M., Basile J.N., Bethel A., Colhoun H.M., Cukierman-Yaffee T., Cushman W.C., DIaz R., Franek E., García-Pérez L.E., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Xavier D.Fuentes:googlescopusEffect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: The glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE)
ArticleAbstract: OBJECTIVE-To evaluate the effects of insulin glargine and n-3 polyunsaturated fatty acid (n- 3FA) suPalabras claves:Autores:Bosch J.J., DIaz R., Dyal L., Gerstein H.C., Hâncu N., Hanefeld M., Krum H., Lonn E.M., McQueen M.J., PATRICIO LOPEZ -JARAMILLO, Ramachandran A., Rydén L.E., Smith S., Yusuf S.Fuentes:googlescopusDulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
ArticleAbstract: Background: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascularPalabras claves:Autores:Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Riesmeyer J.S., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.Fuentes:googlescopusDulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
ArticleAbstract: Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) inPalabras claves:Atrial Fibrillation, atrial flutter, dulaglutide, glucagon-like peptide-1 receptor agonists, Type 2 DiabetesAutores:Avezum A.J., Basile J.N., C. Gerstein H., Conget I., Cushman W.C., Dagenais G.R., Hoover A., Jansky P., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusDulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
ArticleAbstract: Background: Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people wPalabras claves:Autores:Abella M., Alebuena A., Almagro S., Amoroso E., Anadon P., Andreu E., Aristimuño G., Arzadun M., Atisso C.M., Avezum A.J., Barbieri M., Barcudi R., BARTOLACCI I.P., Basile J.N., Bolobanich G., BORDONAVA A.P., Botros F.T., Bustamante Labarta M., Bustos B., CACCAVO A., Camino A., Cantero M., Cardona-Munoz E.G., Carignano M., CARTASEGNA L.U.I.S., Chung N., Cipullo M., Colhoun H.M., Commendatore V., Conget I., Conosciuto V., Costamagna O., Crespo C., Cuello J.L., Cuneo C.A., Cushman W.C., Cusimano S., Dagenais G.R., Dean S., DIaz R., Dituro C., Dominguez A., Dyal L., Farah M., Fernandez A., Fernandez F., Ferrari A., Flammia P., Franek E., Fuentealba J., Gallardo K.B., Garcia C., GARCIA DURAN R.O., GARRIDO M., Gavicola R., Gerbaudo C., Gerstein H.C., Gilli G., Giotto A.P., Godoy Bolzán P., Gomez Vilamajo O., Guerlloy F., Guridi C., Gutierrez Garrido N., Hall S., Hâncu N., Hanefeld M., HASBANI E., Hermida S., Holt S., HOMINAL M.A., HRABAR A., Ingaramo A., Izzicupo A., Jansky P., Keltai M., Krynski M., Lagrutta M., Lakshmanan M., Lanas F.T., Lanchiotti P., Langhe M., Leiter L.A., Leonard V., Llanos J., López-Santi R., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T., Washington Stalin García Cuenta, Wong G., Xavier D.Fuentes:googlescopusNovel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
ArticleAbstract: Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationshiPalabras claves:cardiovascular events, cognitive impairment, Composite outcome, death, Geometric mean, MACE, risk factor, strokeAutores:Angelyn Bethel M., Basile J.N., Cardona-Munoz E.G., Conget I., Cukierman-Yaffee T., Dagenais G.R., Franek E., Gerstein H.C., Hall S., Hâncu N., Jansky P., Lakshmanan M., Lanas F., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Ramasundarahettige C., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu H.H., Temelkova-Kurktschiev T.Fuentes:googlescopusPantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
ArticleAbstract: Background & Aims: Antiplatelets and anticoagulants are associated with increased upper gastrointestPalabras claves:drug, Heart Disease Prevention, Stomach, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Commerford P.J., Connolly S.J., Cook-Bruns N., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus